Are health-care investments recession-proof?
In both good and bad economic times, people will inevitably get sick and require health care. So when markets are down, health care may be…
- By: Yaelle Gang
- January 31, 2020 December 13, 2020
- 08:34
In both good and bad economic times, people will inevitably get sick and require health care. So when markets are down, health care may be…
An international outbreak of respiratory illness sparked by a novel coronavirus has spread from its origins in central China to at least 11 countries, with…
Several factors are pointing to a possible rebound in emerging market stocks this year. Stocks in China and other developing economies notched solid gains in…
Global shares, represented by the MSCI world index, ended 2019 at an all-time high. Their robust 9.5 per cent per annum return during the 2010s…
A topic that has received a lot of attention recently in many markets, especially the United States, is the fall in the number of listed…
Global stock markets took another hit Monday while oil and gold prices surged in response to the escalating tensions in the Middle East following the…
Shareholder environmental activism has been growing in popularity with institutional investors, but is it working? The New York City pension system implemented a boardroom accountability…
After a year of nirvana, investors may need to get ready for something a little more normal. Markets are coming off a fabulous 2019, where…
Two questions seem to occupy pundits and popular media these days. One is why interest rates are negative and what this means. The other is…
Connecticut state Treasurer Shawn Wooden, who oversees $37 billion in public pension funds, will announce Tuesday plans to reallocate $30 million worth of shares in…
Japanese Prime Minister Shinzō Abe’s economic policies, known as ‘Abenomics,’ have led to big improvements in corporate governance in the country, says Iain Campbell, a…
New research from Greenwich Associates has found that institutional players have allocated US$47 billion to liquid alternative exchange traded funds, comprising a fair chunk of…
Passive investing is immensely popular, with assets in passive funds having cleared US$13 trillion, globally. But can active investors take advantage of the new landscape…
Investors seeking regular income are limited because traditional sources aren’t producing the results they used, says Dave Makarchuk, partner and Western Canada wealth business leader…
Meat alternatives have garnered a lot of attention lately off the back of Beyond Meat’s listing on the NASDAQ and its subsequent rocket-propelled rise in…
Rising with the growth of smartphones, lithium has been a hot material in the investment world for a few years. And many in the institutional…
While there are signals that the global economy is slowing down, it doesn’t appear to be quite at recession levels. “That has major investment implications,”…
Direct exposure to emerging market equities may not be the best way to capture the growth potential of those economies. Instead, investors looking for the…
With no actively managed pure Canadian momentum strategies available in Canada according to research by Hillsdale Investment Management Inc., it decided to fill the market…
Looking back at the first half of 2019, bond and equity markets seem to be telling opposing stories, according to T.Rowe Price’s mid-year market outlook.…
The market value of Canadian trusteed pension fund assets decreased by 1.3 per cent in Q4 2018 compared to the previous quarter, landing at $1.87…
With a challenging backdrop to the current investment landscape, certain topics are continually resurfacing when chief investment officers speak with asset owners. The conversation is dominated…
Last spring, U.S. President Donald Trump tweeted that trade wars are easy to win. Last Friday, however, he tweeted the U.S. and China have really…
Though data has been a buzzword in the investment world for years, new and unique types of data have the potential to add value to both quantitative…
The Canada Pension Plan Investment Board is acquiring a US$1.3 billion stake in LifeArc’s royalty interests on worldwide sales of immunotherapy drug Keytruda through its European…